SCHEMBL24364714

SCHEMBL24364714

CC(CN(C)C)C(=O)/C=C/c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TDP1 Q9NUW8 2/20 0.49
GLA P06280 1/20 0.49
ALDH1A1 P00352 4/20 0.48
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
PLIN1 O60240 2/20 0.47
LMNA P02545 2/20 0.47
RECQL P46063 2/20 0.47
PLIN5 Q00G26 2/20 0.47
ABHD5 Q8WTS1 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24366504 0.84 HSD11B1 (0.50) ALDH1A1MAPTSMN1; SMN2LMNAKMT2A
SCHEMBL11859410 0.83 TDP1 (0.48) NPC1L3MBTL1TDP1GLAALDH1A1
SCHEMBL11859406 0.83 TDP1 (0.48) NPC1L3MBTL1TDP1GLAALDH1A1
SCHEMBL7945432 0.81 TDP1 (0.53) NPC1L3MBTL1TDP1GLAALDH1A1
SCHEMBL7933720 0.81 TDP1 (0.53) NPC1L3MBTL1TDP1GLAALDH1A1
Maleic Acid SCHEMBL11865993 0.79 HDAC3 (0.50) NPC1L3MBTL1TDP1GLAALDH1A1
Maleic Acid SCHEMBL11866000 0.79 HDAC3 (0.50) NPC1L3MBTL1TDP1GLAALDH1A1
SCHEMBL31145160 0.78 PADI4 (0.38) NPC1MAPTHDAC3HDAC1HDAC6
SCHEMBL24365575 0.78 PADI4 (0.38) NPC1MAPTHDAC3HDAC1HDAC6
SCHEMBL29323985 0.78 PTGS2 (0.45) ALDH1A1CYP1A2HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 EP disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279219-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 NPC1 39/4885L3MBTL1 3066/4885TDP1 2792/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 NPC1 39/4885L3MBTL1 3066/4885TDP1 2792/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 NPC1 39/4885L3MBTL1 3066/4885TDP1 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.